- Home
- MRNA vs TEVA Comparison
MRNA vs TEVA Comparison
Compare MRNA & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNA
- TEVA
- Stock Information
- Founded
- MRNA 2010
- TEVA 1901
- Country
- MRNA United States
- TEVA Israel
- Employees
- MRNA N/A
- TEVA N/A
- Industry
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- TEVA Biotechnology: Pharmaceutical Preparations
- Sector
- MRNA Health Care
- TEVA Health Care
- Exchange
- MRNA Nasdaq
- TEVA Nasdaq
- Market Cap
- MRNA 16.0B
- TEVA 18.4B
- IPO Year
- MRNA 2018
- TEVA N/A
- Fundamental
- Price
- MRNA $24.72
- TEVA $13.65
- Analyst Decision
- MRNA Hold
- TEVA Strong Buy
- Analyst Count
- MRNA 20
- TEVA 6
- Target Price
- MRNA $54.47
- TEVA $24.00
- AVG Volume (30 Days)
- MRNA 10.2M
- TEVA 12.0M
- Earning Date
- MRNA 05-01-2025
- TEVA 05-07-2025
- Dividend Yield
- MRNA N/A
- TEVA N/A
- EPS Growth
- MRNA N/A
- TEVA N/A
- EPS
- MRNA N/A
- TEVA N/A
- Revenue
- MRNA $3,236,000,000.00
- TEVA $16,544,000,000.00
- Revenue This Year
- MRNA N/A
- TEVA $5.31
- Revenue Next Year
- MRNA $22.07
- TEVA $1.18
- P/E Ratio
- MRNA N/A
- TEVA N/A
- Revenue Growth
- MRNA N/A
- TEVA 4.41
- 52 Week Low
- MRNA $23.15
- TEVA $12.47
- 52 Week High
- MRNA $170.47
- TEVA $22.80
- Technical
- Relative Strength Index (RSI)
- MRNA 36.68
- TEVA 37.96
- Support Level
- MRNA $23.68
- TEVA $13.24
- Resistance Level
- MRNA $27.21
- TEVA $13.83
- Average True Range (ATR)
- MRNA 2.06
- TEVA 0.80
- MACD
- MRNA -0.03
- TEVA -0.03
- Stochastic Oscillator
- MRNA 26.98
- TEVA 38.44
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About TEVA Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.